Recombinant Cynomolgus monkey CTLA4 Protein

• Cat.No.: CTLA4-647C
• Product Overview: Recombinant Cynomolgus monkey CTLA4 protein without tag was expressed in HEK293.

Specification

• Description: This gene is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases.
• Source: HEK293
• Species: Cynomolgus monkey
• Form: Lyophilized
• Molecular Mass: 14.1 kDa
• Protein Length: 223
• AA Sequence: MACLGFQRHKARLNLATRTRPYTLL FSLLFIPVFSKAMHVAQPAVVLANS RGIASFVCEYASPGKATEVRVTVLR QADSQVTEVCAATYMMGNELTFLDD SICTGTSSGNQVNLTIQGLRAMDTG LYICKVELMYPPPYYMGIGNGTQIY VIDPEPCPDSDFLLWILAAVSSGLF FYSFLLTAVSLSKMLKKRSPLTTGV YVKMPPTEPECEKQFQPYFIPIN
• Purity: > 98%
• Applications: WB; ELISA; FACS; FC
• Stability: This bioreagent is stable at 4 centigrade (short-term) and -70 centigrade(long-term). After reconstitution, sample may be stored at 4 centigrade for 2-7 days and below -18 centigrade for future use.
• Storage: At -20 centigrade.
• Concentration: 1 mg/mL
• Storage Buffer: PBS (pH 7.4-7.5). Sterile-filtered colorless solution.
• Reconstitution: Reconstitute in sterile distilled H2O to no less than 100 μg/mL; dilute reconstituted stock further in other aqueous solutions if needed. Please review COA for lot-specific instructions. Final measurements should be determined by the end-user for optimal performance.

Gene Information

• Gene Name: CTLA4 cytotoxic T-lymphocyte-associated protein 4 [ Macaca mulatta (Rhesus monkey) ]
• Official Symbol: CTLA4
• Synonyms: CTLA4; cytotoxic T-lymphocyte-associated protein 4; cytotoxic T-lymphocyte protein 4; CD152 protein; cytotoxic T-lymphocyte protein 4 isoform CTLA4-TM; CTLA-4
• Gene ID: 705673
• mRNA Refseq: NM_001044739
• Protein Refseq: NP_001038204
• UniProt ID: A0A2K6E1V4

Reviews

04/17/2019

It has become an indispensable tool in my experiments, consistently meeting my needs and providing valuable insights.

11/25/2018

The CTLA4 protein is a top-quality product that is sure to fulfill my experimental requirements.

01/28/2017

the ease of use and compatibility of the CTLA4 protein with various techniques further enhances its appeal.

Q&As

Are there ongoing clinical trials exploring CTLA-4 inhibitors in combination with other immunotherapies?

Yes, several clinical trials are investigating the combination of CTLA-4 inhibitors with PD-1 inhibitors and other immunotherapies to improve the overall effectiveness of cancer treatment.

How does the expression of CTLA-4 vary in different types of immune cells?

CTLA-4 is expressed on various immune cells, including T cells, regulatory T cells (Tregs), and some B cells, contributing to its diverse immunoregulatory functions.

In what ways can CTLA-4 be utilized in organ transplantation?

Modulating CTLA-4 may have applications in organ transplantation by suppressing the immune response against transplanted tissues and reducing the risk of rejection.

How does CTLA-4 contribute to the maintenance of immune tolerance?

CTLA-4 is involved in the suppression of autoreactive T cells, contributing to the prevention of autoimmune responses by maintaining immune tolerance.

How does CTLA-4 blockade differ from PD-1/PD-L1 blockade in cancer immunotherapy?

While both CTLA-4 and PD-1/PD-L1 inhibitors enhance anti-tumor immune responses, they target different checkpoints in the immune system. CTLA-4 primarily regulates T-cell activation in the early stages, whereas PD-1/PD-L1 acts later in the immune response.